

1 **Concomitant Control of Mechanical Properties and Degradation in Resorbable Elastomer-like**
2 **Materials Using Stereochemistry and Stoichiometry for Soft Tissue Engineering**

3 Mary Beth Wandel^{1#}, Craig A. Bell^{2,3,4#}, Jiayi Yu^{1#}, Maria C. Arno⁵, Nathan Z. Dreger¹, Yen-
4 Hao Hsu¹, Anaïs Pitto-Barry², Joshua C. Worch⁵, Andrew P. Dove^{*5}, Matthew L. Becker^{*6}

5 ¹ Department of Polymer Science, The University of Akron, Akron, OH 44325

6 ² Department of Chemistry, The University of Warwick, Coventry, CV4 7AL, UK

7 ³ Centre for Advanced Imaging, The University of Queensland, St Lucia, Queensland 4072, Australia

8 ⁴ Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St
9 Lucia, Queensland 4072, Australia

10 ⁵ School of Chemistry, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

11 ⁶ Department of Chemistry, Mechanical Engineering and Materials Science, Orthopaedic Surgery,
12 Duke University, Durham, NC 20899

13
14 *E-mail: matthew.l.becker@duke.edu; a.dove@bham.ac.uk

15 # These authors contributed equally to this work

16 **Abstract**

17 Complex biological tissues are highly viscoelastic and dynamic. Efforts to repair or replace cartilage,
18 tendon, muscle, and vasculature using materials that facilitate repair and regeneration have been
19 ongoing for decades. However, materials that possess the mechanical, chemical and resorption
20 characteristics necessary to recapitulate these tissues have been difficult to mimic using synthetic
21 resorbable biomaterials. Herein, we report a series of resorbable elastomer-like materials that are
22 compositionally identical and possess varying ratios of *cis:trans* double bonds in the backbone.
23 These features afford concomitant control over the mechanical and surface eroding degradation
24 properties of these materials. We show the materials can be functionalized post-polymerization with
25 bioactive species and enhance cell adhesion. Furthermore, an *in vivo* rat model demonstrates that
26 degradation and resorption are dependent on succinate stoichiometry in the elastomers and the
27 results show limited inflammation highlighting their potential for use in soft tissue regeneration and
28 drug delivery.

29 Introduction

30

31 Biological tissues are highly viscoelastic and dynamic.^{1,2} These qualities are lacking in
32 synthetic degradable materials that are routinely available and applied to regenerative medicine.³
33 Many of the biomaterials that have been used widely for regenerative medicine, such as poly(*L*-lactic
34 acid) (PLLA) and poly(ϵ -caprolactone) (PCL), are semi-crystalline and do not replicate the elastic
35 properties of native tissues. These materials also exhibit anisotropic degradation as a consequence
36 of the presence of both amorphous and crystalline domains which leads to limited control over the
37 resorption timelines.²⁻⁴ Attempts to engineer elastomeric materials with mechanical properties similar
38 to native tissues have been focused on non-degradable systems.^{5,6} While these have been directed
39 towards obtaining materials that possess the elastic properties of natural rubber, they have not
40 followed its design principles, namely the incorporation of *cis*-1,4 alkene segments, to control the
41 mechanical properties. While synthetic surrogates such as *cis*-1,4-polyisoprene, *cis*-1,4-
42 polybutadiene and analogues are available, each of these materials lack degradable units that
43 facilitate resorption and lack the physical chemical or topological properties necessary to recapitulate
44 a wide variety of tissues.^{2,7} In addition, anionic or metallocene-based polymerization synthesis
45 methodologies are functional group intolerant making the incorporation of bioactive groups pre- or
46 post-polymerization that facilitate specific cellular interactions challenging.

47 Significant efforts have been expended to investigate degradable thermoplastic elastomers
48 for biomaterials applications.⁸⁻²³ However, nearly all elastomer-like materials developed for tissue
49 engineering to date require crosslinking or blending to achieve desirable mechanical and
50 degradation properties.² Polyurethanes can be modified to control degradation by altering the hard
51 segments, soft segments, and chain extenders to include varied amounts of hydrolytically
52 degradable esters, orthoesters, amides, anhydrides, or enzymatically degradable units such as
53 elastase-sensitive amino-acid chains.¹³ The materials are known to degrade heterogeneously on
54 account of anisotropic degradation within the soft block-forming component that leaves non-
55 degraded hard block (typically urethane-based) components and results in exponential decreases in

56 mechanical properties.²⁴ Beyond this, the resultant degradation byproducts are acidic and often elicit
57 a strong inflammatory response.^{2,13,24,25} To overcome the lack of hard block degradation, poly(ester
58 urethane) ureas (PEUUs), which contain biodegradable urea linkages, have also been
59 investigated.¹² These materials however largely retain bulk erosion profiles and like polyurethanes,
60 the hard-soft block ratio dictates both the mechanical and degradative properties in a manner that
61 cannot be decoupled.¹⁰ Chemically crosslinked polymers like poly(glycerol sebacate) (PGS) and
62 similar derivatives are capable of achieving elastic properties that mimic several soft tissues, and
63 can achieve varied degradation rates by altering the crosslink density during preparation, but these
64 materials are difficult to synthesize reproducibly, cannot be thermally processed after crosslinking,
65 and are known to degrade too rapidly for long-term regeneration strategies (around 6 weeks *in*
66 *vivo*).^{13,17,26-28}

67 The need to change the chemical structure to vary the mechanical properties presents the
68 central dogma in these materials that has made it difficult to decouple the effects of chemistry and
69 mechanical properties on degradability and tissue regeneration. Until now, no synthetic resorbable
70 elastomer or elastomer-like polymer system have afforded independent control of mechanical
71 properties and degradation *de novo*.² We recently reported the first metal-free, stereocontrolled step-
72 growth polymerization *via* a nucleophilic thiol-yne addition which yielded a series of thermally-
73 processable elastomers in which the mechanical properties were controlled by the double bond
74 stereochemistry.^{5,29} The double bond stereochemistry (% *cis*) in each thiol-yne step growth polymer
75 was tuned based on solvent polarity and organic base which is able to preferentially directs the thiol
76 addition to the *cis* stereochemistry. Truong et al. have shown that low and high % *cis* can be
77 achieved by changing the base from Et₃N (pK_a=10.75) to DBU (pK_a=13.5) while maintaining the
78 solvent (CDCl₃). However, moderately high % *cis* subunits can be achieved with Et₃N base when a
79 more polar solvent such as DMSO is used. All high % *cis* polymers were formed using DBU/CHCl₃
80 but lower % *cis* contents were formed by using Et₃N and varying compositions of DMF and CHCl₃
81 (17:3, 7:3, and 100% DMF). However, in this initial report, the materials were non-degradable and

82 display no significant mass loss over one year in 5 M KOH_(aq) solution, most likely a result of
83 resistance to ester hydrolysis due to conjugation.

84 In order to translate these elastomer-like systems into regenerative medicine applications, a
85 new series of polymers have been developed that incorporates degradable succinate-based
86 monomer units (Figure 1A). By altering the stoichiometry of succinate incorporation, the degradation
87 rate of the material can be tuned precisely while retaining control over the mechanical properties by
88 maintaining the *cis/trans* stereochemistry of the double bond (Figure 1B). This structural control
89 enables the independent tuning of mechanical and degradative properties and thus overcomes a
90 major hurdle in biomaterials. Furthermore, as a consequence of the highly hydrophobic nature of the
91 material, they likely exhibit surface erosion behavior (Figure 3B). In turn, these materials display
92 excellent *in vitro* cell viability and have been implanted *in vivo* to assess degradation and the
93 inflammatory response over 4 months in a subcutaneous rat model.

94

95 **Results and Discussion**

96 Succinic acid is found naturally within the body and can be metabolized by the Krebs cycle.³⁰ As
97 such, it provided the ideal building block from which to introduce non-conjugated esters into the
98 elastomer structure with which to influence biodegradation rates. Creation of a series of materials
99 using a nucleophilic thiol-yne polymerization methodology was undertaken to target high *cis*- content
100 at comparable molar mass ($M_w = 100 - 150$ kDa) using propane-1,3-diyl dipropiolate (C_{3A}, **1**) in
101 combination with equimolar dithiols composed from mixtures of 1,6-hexanedithiol (C_{6S}) and the
102 succinate-derived dithiol monomer bis(3-mercaptopropyl) succinate (**2**) (Table 1).

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

The ability to significantly influence mechanical properties by simply altering the *cis:trans* ratio by
judicious choice of polymerization catalyst and solvent enables the manipulation of the materials'
mechanical properties without changing the fundamental composition of the copolymer and thus
affecting its degradation behavior. In order to demonstrate this, a series of materials were

111 synthesized at constant ratio of C_{6s} and succinate-based monomer, **2**, (9%) while varying the
112 *cis:trans* ratio between 62 and 80% which represents more than an order of magnitude change in
113 elastic modulus of the material. The stoichiometric ratio of **2:3** and the %*cis* is determined easily
114 from the splitting of the vinyl proton doublets at $\delta = 5.7$ and 7.7 ppm (*trans*, 15 Hz) and $\delta = 5.8$ and
115 7.1 ppm (*cis*, 9 Hz), respectively, in the ¹H NMR spectra of the polymers in solution (Figure 1B).

116
117 Uniaxial tensile testing revealed that increasing the incorporation of the succinate-based
118 monomer **2** led to decreased ultimate tensile strength and Young's modulus and increased
119 elongation at break (Figure 2B, Table 2). This behavior is consistent with a more elastic material that
120 is expected from the interruption of crystallinity through the introduction of ester groups into the main
121 chain that disrupt chain packing and increase chain mobility. These findings were confirmed *via*
122 differential scanning calorimetry (DSC) which showed that increasing %*cis* without altered succinate
123 content increased the glass transition temperature in line with results from our previous work.^{5,29}
124 Significantly, the materials exhibit high thermal stability and the onset of degradation temperatures
125 exceeds 350 °C. These traits are critical for thermal processing and fabrication.

126
127 An *in vitro* investigation of the hydrolytic swelling and degradation behavior showed the polymers
128 to be chemically stable with no visible degradation in PBS at ambient temperature over a 1-month
129 period (**Figure 3**). In order to accelerate the hydrolytic degradation process, the samples were
130 incubated in 5 M KOH (aq) solution at ambient temperature. The data show that the materials with
131 increased succinate-based monomer, **2**, yielded faster rates of degradation. Importantly, the mass
132 loss profiles are nearly linear in nature and show no evidence of accelerated degradation as a result
133 of acidosis and swelling *via* bulk erosion. The dimensions of the materials were noted to decrease
134 concomitantly with time which is highly indicative of a surface erosion mechanism. SEM analysis of
135 test substrates (Figure 3B) exposed to accelerated degradation conditions indicates uniform
136 degradation and pitting that confirms surface erosion as the most prevalent degradation process.
137 Taken together, these observations demonstrate that, unlike any other degradable biomaterials, the

138 mechanical and degradation properties of these elastomer-like polymers can be controlled
139 independently. This is a distinct difference from known polyesters. To demonstrate the potential, by
140 careful control over double bond stereochemistry and succinate monomer (**2**) content, we prepared
141 materials that displayed comparable degradation rates but markedly different mechanical properties
142 and *vice versa* (comparable mechanical properties with markedly different degradation rates –
143 (Figure 2A&B). The control over each of these properties will be critical to future applications where
144 designers will need to engineer subtle changes without returning to new synthetic methods.

145
146 To investigate the potential for use in biomaterial applications, cell viability, spreading and
147 proliferation assays were used as an initial method to determine the cellular responses to the
148 elastomer-like polymers. Human mesenchymal stem cells (*hMSCs*) and MC3T3 cells were cultured
149 on glass slides spin-coated with each material variant or on the control polymer, poly(*L*-lactide),
150 PLLA. Cell viability was found to be higher than 95% on all samples using a Live/Dead® assay. Cell
151 adhesion and spreading was assessed by staining F-actin, vinculin-labeled focal adhesion contacts,
152 and cell nuclei and revealed that the *hMSCs* adopted an elongated and spindle-like shape on all
153 samples. Cell proliferation was measured with a PrestoBlue® metabolic assay, after 24 h, 3 days
154 and 7 days of incubation. After 7 days the population of cells on each sample increased
155 approximately 5 times the original concentration (Supplemental Figure 23).

156 One of the key aspects of a translationally relevant material is the ability to control the placement
157 and concentration of functional species (drug, peptide, protein) on the surface of a materials where
158 the group is bioavailable to the surrounding cells and tissues.³¹ While many methods are available
159 for peptide polymer conjugation, we designed a dialkyne monomer, but-2-yne-1,4-diyl dipropiolate
160 (**3**) that possesses an internal triple bond. As a consequence of the increased distance from the
161 electron withdrawing groups, the reactivity of internal alkynes is distinctly different than terminal
162 alkynes. The internal alkynes were found to be stable during the nucleophilic thiol-yne addition
163 polymerization process with C_{3A} (**1**) and C_{6S} (1,6-hexane dithiol) as comonomers which left it
164 available for selective post-polymerization functionalization of the resulting materials (Figure 4E).

165 Following the polymerization and a film casting process, a Megastokes®-673-azide dye surrogate
166 (Figure 4F) was covalently tethered to the internal alkyne functionalized poly(bis(4-
167 (propioloyloxy)but-2-yn-1-yl)-3,3'-(hexane-1,6-diylbis(sulfanediyl))) using Cp*RuCl(COD) as a
168 catalyst.³² After washing, the film remained fluorescent thus evidencing the conjugation of the dye to
169 the polymer. To extend the concept and show utility from a biomaterials viewpoint, we also used this
170 methodology to attach an azide-functionalized GRGDS peptide to the films. While only an initial
171 demonstration, the presence of the adhesion peptide had a distinct influence on the cell adhesion
172 and spreading properties (Figure 4G and 4H). Following peptide conjugation, increased cell
173 adhesion, spreading and integrin-associated actin fiber formation was evident in the RGD
174 derivatized films relative to the unfunctionalized films. Future studies are developing this technique
175 to apply other bioactive groups designed to influence specific cellular activities.

176
177
178

179 The lack of cytotoxicity and enhanced cellular activity confirmed that the thiol-yne
180 stereoelastomer materials could be implanted *in vivo* for tissue compatibility studies. Elastomeric
181 discs possessing various *cis* content and succinate stoichiometry were implanted subcutaneously for
182 4 months to observe the degradation behavior and tissue inflammatory responses *in vivo*.
183 Significantly, no gross inflammation, which would appear as a dense calcified capsule, was evident
184 from macroscopic images of the samples taken at each timepoint (Figure 5B). Sections stained with
185 hematoxylin and eosin (H&E) were analyzed for inflammatory responses in the form of fibrous
186 capsule formation. Sections stained with H&E were also assessed for inflammatory cell infiltration.
187 Fibrous encapsulation occurred as expected, and the granuloma grew thicker over 4 months of
188 incubation with no significant difference compared to PLLA (Figure 5). The granuloma was less than
189 200 μm thick for all samples, which has previously been reported as acceptable in terms of tissue
190 compatibility for long-term implants.^{4,33,34} This is indicative of the tunable degradation profiles from
191 varied succinate content as increasing implant degradation rates correlates with greater cellular
192 remodeling processes.³⁴

193

194 H&E slides were quantitatively analyzed for neutrophils, lymphocytes, plasma cells, single
195 macrophages, multinucleated giant cells, and necrosis at the 1, 2, and 4-month time points following
196 a subcutaneous rat implant model. Additionally, each slide was assessed for inflammatory cell
197 infiltrate based on a modified scoring system outlined by the International Organization for
198 Standardization (ISO 10993-6 Annex E) by a board-certified veterinary pathologist. The numbers of
199 inflammatory cells were estimated in a 400× field using light microscopy images, and a score was
200 assigned for each inflammatory cell type as denoted in Table 3. The most severely affected region of
201 the evaluated tissue was utilized to assign a score. The severity of necrosis was judged by the
202 percentage of the fibrous capsule exhibiting evidence of necrosis (pyknosis, karyorrhexis, or
203 karyolysis) not including any inflammatory cell infiltrate. Comparisons were made between
204 elastomers with the 80% *cis* content and containing a range of %succinate content (Figure 2). A
205 striking difference was apparent between elastomers with lower succinate content from 10-50%
206 compared to the 100% succinate-containing elastomer after only one month, and increasingly over 4
207 months (Table 2).

208 Full tissue infiltration into the polymer space occurred as the 80% *cis* / 100% succinate polymer
209 degraded (Figure 5). This was noted by an increase in the total number of inflammatory cells into the
210 capsule space with a total score of 8.6 ± 1.5 , 9.1 ± 1.2 , and 10.9 ± 1.9 for 1, 2, and 4-months
211 respectively. This was noticeably greater than all other materials which elicited total scores ranging
212 between $4.3 \pm 1.2 - 4.9 \pm 1.8$, $3.8 \pm 1.4 - 4.7 \pm 1.7$, and $2.6 \pm 1.3 - 4.0 \pm 2.0$ for 1, 2, and 4-months
213 respectively. For reference, medical-grade polypropylene has scored around **7.5** in a similar recent
214 study.³⁴ While used widely in the clinic, this value would be noted as a persistent low level
215 inflammatory response. In each of the materials above, the reported values are 30-50% less than
216 polypropylene. The investigation of these materials in more translationally relevant applications is
217 ongoing.

218 Very few multinucleated giant cells were found surrounding the implants and there was no
219 evidence of necrosis, even at extended timepoints. The only samples with a few multinucleated giant

220 cells were the 80% *cis* / 50% succinate and 80% *cis* / 100% succinate elastomers, where giant cells
221 were found infiltrating degraded polymer areas. Multinucleated giant cells attempt to encapsulate
222 portions of the foreign body that have broken away as well as releasing factors that degrade
223 extracellular matrix and cause damage and degradation of the implanted material, and thus are
224 regarded as an obstacle for clinical translation of biomaterials.^{35,36} The absence of multinucleated
225 giant cells shows a limited foreign body response over the period of the experiment. Macrophage
226 staining of 4 month 80c100s polymer shows evidence of a robust inflammatory response that is
227 expected to occur during the degradation, resorption and remodeling process. CD68 was used as a
228 pan-macrophage (M0, blue) marker, CCR7 was used to indicate classically activated macrophages
229 (M1, red), and CD206 was used to indicate the presence of alternatively activated macrophages
230 (M2, green). Non-specific control staining shows subtle autofluorescence of the stereoelastomers
231 inhibits quantitative analysis of macrophage presence. The presence of M2 macrophages indicates
232 that a transition to a remodeling phase is likely occurring.³⁷ Trichrome staining shows no evidence
233 of capsule formation in the stereoelastomer samples while a thicker layer of collagen deposition
234 surrounds the PLLA implant. The semi-crystalline PLLA control material in this study is likely not
235 degrading quickly compared to previous literature reports of amorphous PDLLA where
236 multinucleated giant cell numbers were extremely high.^{38,37} The surface chemistry differences
237 imparted by the crystalline domains of the materials play an important role in the amount and
238 conformation of protein absorption, and this subsequently affects the process of multinucleated giant
239 cell formation.

240 Picrosirius red (PSR) staining is a commonly used histological technique to visualize collagen in
241 paraffin-embedded tissue sections.³⁹ PSR stained collagen appears red in optical microscopy.
242 However, it is largely unknown that PSR stained collagen also shows a red fluorescence, whereas
243 live cells have a distinct green autofluorescence. As shown in Figure 6, Picrosirius Red staining is
244 present at the edge of the degrading stereoelastomers (1 month) and throughout the site formerly
245 occupied by the degraded 80cis100suc materials after 4 months of subcutaneous incubation. This

246 clearly shows that collagen deposition and maturation occurred throughout the space formerly
247 occupied by the polymer.

248

249 These results, along with a decrease in size of the 80% *cis* / 100% succinate, shows that tissue
250 remodeling and near complete polymer resorption occurs over a 4-month time frame (Figure 5).
251 Remodeling of the degraded polymer over 4 months is comparable to that seen in poly(glycerol
252 succinate) materials after 9 weeks of implantation, suggesting that this material is suitable for tissue
253 regeneration, particularly for situations where the polymer must endure beyond 2 months to provide
254 appropriate mechanical load reinforcement.⁴⁰ Future studies for these materials will observe the
255 effects of degradation and associated inflammation for the slower degrading variants. Many recent
256 findings have noted the importance of fine-tuning degradation rates to match regeneration rates for
257 optimal tissue growth and mechanical reinforcement as needed throughout healing.^{2,24,29,41}
258 Significantly, this study has shown significant tissue growth into non-functionalized bulk implants
259 where inflammation and granuloma formation was limited. The versatility in the synthesis of these
260 elastomer-like polymers with controlled variability of mechanical properties and degradation rates
261 marks significant progress in the field of degradable biomaterials.

262 In summary, we have developed a series of highly tunable and resorbable elastomer-like
263 polymers that afford concomitant control of mechanical and degradation properties. These materials
264 have shown excellent cellular responses *in vitro* and possess limited inflammatory responses *in vivo*.
265 Most importantly, the variants containing 100% succinate incorporation were capable of degrading *in*
266 *vivo* over a period of four months and were replaced with mature and developing tissues. These
267 responses show that these materials are non-toxic and further, will provide a new developmental
268 platform for regeneration of tissues with varied mechanical and degradation requirements. Future
269 studies on these materials will include optimization of material properties, control/inhibition of
270 crosslinking, post-polymerization functionalization with bioactive species and assessment of
271 mechanical properties throughout degradation.

272

273 **Acknowledgements**

274 The authors are grateful for financial support from the Biomaterials Division of the National
275 Science Foundation (DMR-1507420), the W. Gerald Austen Endowed Chair in Polymer Science and
276 Polymer Engineering via the John S. and James L. Knight Foundation (MLB), ERC Grant (Number
277 681559) (APD) and the National Health and Medical Research Council (NHMRC) of Australia (APP
278 1054569) (CAB). The authors would like to thank Gina M. Policastro for monomer synthesis, James
279 A. Wilson for polymer precursor synthesis, Derek Luong for help with *in vitro* assessments, Dr.
280 Christopher Klouk and Dr. Christopher Premanandan for assistance with histological assessments.

281

282 **Methods**

283 **Materials:** The following chemicals were used as received: acetone (Sigma-Aldrich, $\geq 99.0\%$),
284 chloroform (CHCl_3 : VWR Chemicals, 99%), d-chloroform (CDCl_3 : Apollo, $> 99\%$), 1,8-
285 diazabicyclo[5.4.0]undec-7-ene (DBU: Sigma-Aldrich, 98%), diethyl ether (Et_2O : Sigma-Aldrich, \geq
286 99.8%), *N,N* dimethylformamide (DMF: Fisher Scientific, LR grade), 2,6-di-*tert*-butyl-4-methylphenol
287 (BHT: Alfa Aesar, 99%), ethyl acetate (EtOAc : Fisher Scientific, LR grade), hexane (Hex: VWR
288 Chemicals, 99%), magnesium sulfate (MgSO_4 : anhydrous, Fisher Scientific, LR grade), 3-mercapto-
289 1-propanol (Tokyo Chemical Industry Ltd. UK, 96%), 1,3-propanediol (Sigma-Aldrich, 98%), propionic
290 acid (Acros Organics, 98%), silica gel (SiO_2 : Apollo Scientific, 40-63 micron), sodium chloride (NaCl :
291 Fisher Scientific, $> 99\%$), sodium hydrogen carbonate (NaHCO_3 : Fisher Scientific, $> 99\%$), sulfuric
292 acid (Fisher Scientific, $> 95\%$), triethylamine (Et_3N : Fisher Scientific, LR grade). 1,6-hexanedithiol
293 (Sigma-Aldrich, $\geq 97\%$) was vacuum distilled prior to use and stored in Young's tapped ampoules
294 under N_2 . Poly(*L*-lactic acid) (PLLA) (Ingeo™ Biopolymer 3100HP) was ordered from NatureWorks.

295

296 **Molecular Structure and Thermal Characterization**

297 Size exclusion chromatography (SEC) analyses were performed on a system composed of a
298 Varian 390-LC-Multi detector using a Varian Polymer Laboratories guard column (PLGel 5 μM , 50 \times
299 7.5 mm), two mixed D Varian Polymer Laboratories columns (PLGel 5 μM , 300 \times 7.5 mm) and a
300 PLAST RT autosampler. Detection was conducted using a differential refractive index (RI) detector.
301 The analyses were performed in CHCl_3 at 40 $^\circ\text{C}$ and containing 0.5% w/w Et_3N at a flow rate of 1.0
302 mL/min. Linear polystyrene (PS) ($162 - 2.4 \times 10^5 \text{ g}\cdot\text{mol}^{-1}$) standards were used to calibrate the

303 system. EcoSEC HLC-8320 GPC (Tosoh Bioscience LLC, King of Prussia, PA) equipped with a
304 TSKgel GMH_{HR}-M mixed bed column and refractive index (RI) detector was performed to analyze
305 poly(bis(4-(propioloyloxy)but-2-yn-1-yl)-3,3'-(hexane-1,6-diylbis(sulfanediyl))) (**10**). Molecular mass
306 was calculated using a calibration curve determined from polystyrene standards (PStQuick MP-M
307 standards, Tosoh Bioscience, LLC) with DMF with 0.1 M LiBr as eluent flowing at 1.0 mL·min⁻¹ at
308 323K, and a sample concentration of 3 mg·mL⁻¹

309 Nuclear magnetic resonance (¹H, ¹³C) spectra were recorded in CDCl₃ on a Bruker DPX-400
310 spectrometer at 298 K. Chemical shifts are reported as δ in parts per million (ppm) and referenced to
311 the chemical shift of the residual solvent resonances (CDCl₃ ¹H: δ = 7.26 ppm, ¹³C: δ = 77.16 ppm).
312 The resonance multiplicities are described as s (singlet), d (doublet), t (triplet), q (quartet) or m
313 (multiplet).

314 Thermogravimetric analysis (TGA) (Q500, TA Instruments, New Castle, DE) was performed over
315 a temperature range from 0 to 600 °C at a heating rate of 10 °C/min. A 5% loss in mass was used to
316 determine the onset temperature of degradation (T_d).

317 Differential scanning calorimetry (DSC) (Q2000, TA Instruments, New Castle, DE) was used with
318 a temperature range from -20 to 200 °C and a scanning rate of 10 °C/min in a
319 heating/cooling/heating mode to determine glass transition temperatures (T_g) of polymers obtained
320 during the second heating cycle.

321

322 **Monomer Synthesis**

323 Propane-1,3-diyl dipropiolate (C_{3A}, **1**): 1,3-propanediol (20.00 g, 0.263 mol) was added to a 1 L
324 single neck round bottom flask. To this was added toluene (100 mL) and benzene (100 mL). Two
325 drops of H₂SO₄ were added and the solution was allowed to stir at room temperature for 5 min
326 before adding propiolic acid (50.00 g, 0.714 mol). A Dean-Stark apparatus with condenser was fitted
327 and the reaction was then refluxed for 16 h at 120 °C or until the required amount of water was
328 collected. The solution was then cooled to room temperature and solvent extracted with saturated
329 NaHCO₃ solution (2 x 200 mL) to remove any residual acids. The organic phase was then collected,
330 dried over MgSO₄, filtered and reduced in volume to dryness. The product was then purified on silica
331 gel isocratically using 4:1 hexane/EtOAc and collecting the 1st fraction. After removal of the solvent,
332 the final product was further purified by distillation under high vacuum at 160 °C to yield colorless oil
333 that slightly crystallised on sitting (24.63 g, 52% yield). R_f (3:2 Hex/EtOAc) = 0.43; Melting point: 25
334 °C; ¹H NMR (500 MHz, CDCl₃) δ 4.30 (t, ³J_{HH} = 6.2 Hz, 4H), 2.88 (s, 2H), 2.19 – 1.96 (m, 2H); ¹³C
335 NMR (125 MHz, CDCl₃) δ 152.6, 75.3, 74.5, 62.6, 27.5; ESI-MS Calcd for C₉H₈O₄Na (M+Na): 203.0,
336 Found: 203.0; Anal Calcd for C₉H₈O₄: C 60.00; H 4.48 %. Found: C 59.70; H 4.41 %.

337

338 **Bis(3-mercaptopropyl) succinate (2):** 3-mercaptopropanol (7.30 g, 0.079 mol) was added to a 250
339 mL single neck round bottom flask. To this was added toluene (60 mL) and benzene (60 mL). Two
340 drops of H₂SO₄ were added and the solution was allowed to stir at room temperature for 5 min
341 before adding succinic acid (4.40 g, 0.037 mol). A Dean-Stark apparatus with condenser was fitted
342 and the reaction was then refluxed for 16 h at 120 °C or until the required amount of water was
343 collected. The solution was then cooled to room temperature and solvent removed by vacuum
344 transfer. The product was resolubilized in CHCl₃ (100 mL) and extracted with saturated NaHCO₃
345 solution (2 x 200 mL) to remove any residual acids. The organic phase was then collected, dried
346 over MgSO₄, filtered and reduced in volume to dryness. The product was then purified on silica gel
347 isocratically using 3:2 hexane/EtOAc and collecting the 1st fraction. After removal of the solvent, the
348 final product was further purified by distillation under high vacuum (0.15 Torr) at 220 °C to yield
349 colorless oil (7.8 g, 79% yield). R_f (3:2 Hex/EtOAc) = 0.4; ¹H NMR (400 MHz, CDCl₃) δ 4.21 (t, ³J_{HH} =
350 6.2 Hz, 4H), 2.62 (s, 4H), 2.58 (q, ³J_{HH} = 6.6 Hz, 4H), 1.40 (t, ³J_{HH} = 8.1 Hz, 2H); ¹³C NMR (100 MHz,
351 CDCl₃) δ 172.3, 62.9, 32.9, 29.2, 21.2; ESI-MS Calcd for C₁₀H₁₈O₄S₂Na⁺ (M+Na⁺): 289.1, Found:
352 289.0; Anal Calcd for C₁₀H₁₈O₄S₂: C 45.09; H 6.81 %. Found: C 59.70; H 4.41 %.

353
354 **Sodium propiolate.** Sodium propiolate was synthesized according to the procedure described by
355 Bonnesen *et al.*¹, Sodium hydroxide (0.645 g, 0.016 mol) was dissolved in methanol (50 mL) in a
356 250 mL round-bottom flask and protected from light. The solution was cooled to 0 °C for 10 min.
357 Then propionic acid (1.00 mL, 0.016 mol) was added with stirring. The solution was allowed to warm
358 to ambient temperature and stirred for additional 2 h. The solvent was then removed by rotary
359 evaporation. A white solid product was formed and dried under high vacuum to yield **3** (1.44 g, 97%).
360 The product should be stored in the dark due to light sensitivities. ¹H NMR (300 MHz, CD₃OD) δ
361 2.95 (s, 1H). ¹³C NMR (75 MHz, CD₃OD) δ 160.64, 81.83, 69.12.

362
363 **But-2-yne-1,4-diyl bis(4-methylbenzenesulfonate).** But-2-yne-1,4-diyl bis(4-methylbenzene
364 sulfonate) was synthesized according to the procedure described by Maisonial *et al.*² Briefly, *p*-
365 toluenesulfonyl chloride (24.00 g, 0.126 mol) and 1,4-butyne-1,3-diol (4.00 g, 0.046 mol) were dissolved
366 in Et₂O (300 mL). The mixture was cooled to -15 °C for 15 min before potassium hydroxide (16.00 g,
367 0.285 mol) was added slowly. The resulting solution was stirred at 0 °C for 3 h and poured into ice
368 water (300 mL). When the solution reached ambient temperature, the solution was extracted with
369 DCM (200 mL x 3) and the organic layer was collected, dried with anhydrous Na₂SO₄, filtered and
370 concentrated. The solid was washed with Et₂O (100 mL x 3) and dried under vacuum 24 h to yield **4**
371 (14.66 g, 80%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ 7.77 (d, *J* = 8.8 Hz, 4H), 7.34 (d, *J* =

372 8.8 Hz, 4H), 4.58 (s, 4H), 2.46 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 145.54, 132.80, 130.01 (× 2),
373 128.16 (× 2), 81.04, 57.21, 21.76.

374
375 **But-2-yne-1,4-diyl dipropiolate (3).** Under reduced light conditions, sodium propiolate (7.600 g,
376 0.083 mol) and But-2-yne-1,4-diyl bis(4-methylbenzene sulfonate) (12.00 g, 0.030 mol) were
377 dissolved in DMF (120 mL), and the mixture was heated to 50 °C, and allowed to stir for 24 h. After
378 the reaction was cooled down to ambient temperature, a saturated solution of NH₄Cl (200 mL) was
379 added to the mixture and the reaction was stirred for 10 min. The mixture was extracted with DCM
380 (150 mL × 3) and the organic extracts were combined, extracted with saturated solution of NaHCO₃
381 (150 mL × 3). The organic layer was combined and dried over anhydrous Na₂SO₄, filtered, and
382 concentrated. The residue was purified by flash column chromatography on silica gel
383 (EtOAc/hexanes 1:3; R_f = 0.30). After removal of the solvent, the final product was further purified by
384 distillation under high vacuum at 110 °C to yield a colorless oil (3.76 g, 65%). ¹H NMR (300 MHz,
385 CDCl₃) δ 4.81 (s, 4H), 2.97 (s, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 151.78, 80.60, 76.34, 73.82, 53.28.
386 ESI-MS for C₁₀H₆O₄Na, m/z theoretical: [M+Na]⁺ = 213.02 Da, observed: [M+Na]⁺ = 213.0 Da.

387
388 **General procedure for thiol-yne step growth polymerization.** An example of the thiol-yne step
389 growth polymerization is as follows: 1,6-hexanedithiol (0.73 g, 4.9 × 10⁻³ mol) and **2** (0.32 g, 1.2 × 10⁻³
390 mol) were added to a 20 mL scintillation vial. Propane-1,3-diyl dipropiolate (1.10 g, 6.1 × 10⁻³ mol)
391 was added to the solution by quantitative transfer with CHCl₃ (12 mL). The solution was then cooled
392 to -15 °C with stirring for 15 min before DBU (9 μL, 6.0 × 10⁻⁵ mol) was added. The addition of DBU
393 produced an exotherm causing the solvent to bubble. After 2 min of stirring, the reaction was then
394 allowed to warm to room temperature and continued to stir, during which time the solution became
395 very viscous. After 1 h, the solution was diluted with CHCl₃ (8 mL). The polymer solution was then
396 precipitated into 1:1 diethyl ether/acetone (200 mL) and collected by decanting the supernatant. The
397 polymer was then redissolved in CHCl₃ (20 mL) and reprecipitated into 1:1 diethyl ether/acetone
398 (200 mL). The polymer was again redissolved in CHCl₃ (20 mL) and 100 mg BHT (5 %w/w) was
399 added. The final solution was then precipitated into n-hexane (200 mL), collected by decanting the
400 supernatant, and dried *in vacuo* at room temperature for 24 h. SEC (CHCl₃ + 0.5% Et₃N) M_n = 35.2
401 kDa, M_w = 110.8 kDa, M_p = 106.9 kDa, Đ_M = 3.15. ¹H NMR (CDCl₃, 400 MHz) % incorporation of **2** =
402 18.7%; % *cis* = 79%.

403
404 **Variation of molecular mass.** The molecular mass of the thiol-yne step growth polymers was
405 varied by changing the amount of dithiol in relation to the dialkyne such that the dialkyne was always
406 in excess. Monomer ratios were determined using the extended Carothers equation for one
407 monomer in excess (assuming *p* → 100%).¹

408

409 **Procedure of thiol-yne step-growth polymerization for but-2-yne-1,4-diyl dipropiolate.** 1,6-
410 Hexanedithiol (4.300 g, 0.028 mol) was added into 500 mL round bottom flask and but-2-yne-1,4-diyl
411 dipropiolate (**5**) (5.500 g, 0.029 mol) was added to a 500 mL round bottom flask with 200 mL CHCl₃.
412 The solution was then cooled to -15 °C with stirring for 20 min before DBU (44 μL, 29 mmol) was
413 added in one portion. Notably, the addition of DBU caused the solvent to bubble due to an
414 exothermic reaction. After stirring for 10 min, the reaction was allowed to warm to room temperature
415 and continued to stir. After 1 h, a couple drops of but-2-yne-1,4-diyl dipropiolate **5** in CHCl₃ (5 mL)
416 was added into the reaction solution. After stirring for an additional 30 min, the solution was diluted
417 with CHCl₃ (50 mL) and BHT (0.48 g, 0.002 mol) before the precipitation steps. The polymer solution
418 was then precipitated into diethyl ether (1.5 L) and collected by decanting the supernatant. The
419 polymer was then redissolved in CHCl₃ (150 mL) and reprecipitated into diethyl ether (1.5 L),
420 collected by decanting the supernatant, and dried by high vacuum system at room temperature for
421 24 h to give pale yellow polymer poly(bis(4-(propioloyloxy)but-2-yn-1-yl)-3,3'-(hexane-1,6-
422 diylbis(sulfanediyl))) (**10**) (8.3 g, 85%). SEC (DMF+0.1M LiBr, based on PS standards) $M_n = 24.7$
423 kDa, $M_w = 35.4$ kDa, $D_M = 1.46$. ¹H NMR (CDCl₃, 300 MHz) % *cis*: % *trans* = 78 %: 22 %. DSC: $T_g =$
424 22 °C. TGA: $T_d = 287$ °C.

425

426 **Post-polymerization functionalization with GRGDS peptide.** The end-capped polymer
427 poly(bis(4-(propioloyloxy)but-2-yn-1-yl) 3,3'-(hexane-1,6-diylbis(sulfanediyl))) (**10**) (300 mg; $M_n =$
428 24.7 kDa, $M_w = 35.4$ kDa, $D_M = 1.46$.) and Cp*RuCl(COD) (1 mg, 0.003 mmol) were added to a 100
429 mL two neck round bottom flask and the round bottom flask was evacuated and purged with N₂ three
430 times before dried DMF (40 mL) was added. Then, 3 wt% N₃-GRGDS peptide (FW= 629.63 g/mol; 9
431 mg) was dissolved in dried DMF (5 mL) and added into the reaction solution by syringe and allowed
432 to stir for 12 h. The solution of GRGDS peptide functionalized polymer was precipitated into ethanol
433 (500 mL), collected and dried under vacuum for 24 h to afford GRGDS peptide functionalized
434 polymer poly(bis(4-(propioloyloxy)but-2-yn-1-yl)-3,3'-(hexane-1,6-diylbis(sulfanediyl)))-GRGDS.

435

436 **Mechanical Testing:** Destructive tensile tests were performed to determine the effects of altered
437 *cis*-alkene and succinate incorporation on Young's Modulus (E) and ultimate strain (ϵ_U). Samples
438 ($n=3$) were prepared using vacuum film compression (Technical Machine Products, Cleveland, OH)
439 to press films measuring 50 mm x 50 mm x 0.5 mm. Polymer was preheated at 120 °C for 15
440 minutes, and then compressed at 10,000 lbs of pressure for 4 minutes before cooling rapidly under
441 vacuum. Tensile bars were cut using a custom-made dog bone shaped die cutter and were pulled at

442 several rates to determine the rate at which equilibrium modulus of all samples could be obtained.
443 Rates tested were 0.1, 1, 5, 10 and 20 mm/min. A rate of 10 mm/min was determined to be
444 appropriate. Samples were tested in an Instron® (5567) equipped with a 100 N load cell. The results
445 were recorded using Bluehill® 3 software (Instron®, Norwood, MA). The modulus values quoted are
446 a from the tangent of the initial yield point at low strain where it exists or over the 2-10% strain
447 regime. The results are the average values of 5 (n=5) individual measurements for each material.

448

449 **Accelerated *in vitro* Degradation Studies:** A film in 0.5 mm thickness of each elastomer was
450 prepared from vacuum film compression using the same method as stated above. Discs with 4 mm
451 in diameter were cut from the film and placed in 5 M NaOH solution in the incubator (37 °C, 5% CO₂
452 humidified atmosphere) for up to 200 days. The films absorbed, swell, degraded and the 5 M NaOH
453 solution was changed every week to ensure the degradation process. At specified intervals, the
454 samples were removed, dried and weighed. The results of mass changes are the average values of
455 four (n=4) individual samples for each material at each time point.

456

457 **Biological Reagents:** Human mesenchymal stem cells (*hMSCs*) were ordered from Lonza and
458 used at passage 4 following manufacturer protocols. Standard MC3T3 fibroblasts were obtained
459 from Riken and used at passage 6 following manufacturer protocols. The following reagents were
460 used as received for cell culture and assessment of cellular activity: α -MEM, penicillin (10,000
461 U/mL)/streptomycin (10,000 μ g/mL) (pen/strep), fetal bovine serum (FBS), trypan blue, and the
462 Live/Dead® assay kit were ordered from Life Technologies; trypsin-ethylene diamine tetraacetate
463 acid (EDTA), Dulbecco's phosphate buffered saline (PBS), 1,4-piperazinediethanesulfonic acid
464 (PIPES), polyethylene glycol (PEG, 8000 kDa), paraformaldehyde, Triton™ X-100, sodium
465 borohydride, donkey serum, and secondary donkey anti-mouse IgG-488 antibody were ordered from
466 Fisher Scientific; ethylene glycol-*bis*(2-aminoethylether)-*N,N,N',N'*-tetraacetic acid (EGTA), and
467 mouse monoclonal primary anti-vinculin antibody were purchased from Sigma Aldrich; Rhodamine

468 phalloidin was ordered from VWR; 4',6-diamidino-2-phenylindole (DAPI) nuclear stain and the
469 PrestoBlue® metabolic assay were ordered from Life Technologies Invitrogen™.

470 Ketamine HCl (KetaVed®, 100 mg/mL), Xylazine (AnaSed®, 20 mg/mL), Acepromazine Maleate
471 (PromAce®, 10 mg/mL), Buprenorphine (Buprenex, 0.3mg/mL), sodium pentobarbital
472 (Beuthanasia®-D); Povidone-iodine solution (Vetadine); Modified Masson's Trichrome staining kit
473 was ordered from Scytek Laboratories, Inc.; goat polyclonal primary anti-CD206 (C-20) antibody was
474 ordered from SantaCruz Biotechnology; Mayer's Hematoxylin, Eosin Y, mouse monoclonal primary
475 anti-CD68/SR-D1 (KP1) antibody, rabbit monoclonal primary anti-CCR7 (Y59) antibody, Sodium
476 Citrate Dihydrate, DPX Mountant, Trizma® base (*Tris*(hydroxymethyl)aminomethane) (Acros
477 Organics, 99.85%), Sodium Chloride (NaCl, Acros Organics), and Tween® 20 (Polyethylene glycol
478 sorbitan monolaurate, Acros Organics) were ordered from Fisher Scientific; VECTASHIELD HardSet
479 Mounting Medium was ordered from Vector Laboratories; donkey anti-mouse Alexa Fluor® IgG-350
480 secondary antibody (polyclonal, 2 mg/mL), donkey anti-goat Alexa Fluor® IgG-488 secondary
481 antibody (polyclonal, 2 mg/mL), donkey anti-rabbit Alexa Fluor® IgG-546 secondary antibody
482 (polyclonal, 2 mg/mL) and TRIS-HCl were ordered from Life Technologies Invitrogen™.

483

484 ***In Vitro* Characterization of Cellular Responses to Degradable Elastomers**

485 **Sample preparation and cell culture:** Samples for cell culture studies ($n=5$) were prepared by spin
486 coating a solution of 0.4 wt% polymer in CHCl_3 on a glass coverslip (1 min. at 1000 rpm). Films were
487 spin-coated onto silicon wafers and glass coverslips to determine thickness by ellipsometry on a
488 variable angle spectroscopic ellipsometer (VASE, M-2000 UV- visible-NIR [240-1700 nm] J. A.
489 Woollam Co., Inc.). Angles used were 55-70 degrees in 5 degree increments, and the Cauchy Layer
490 model was used to determine sample thickness, with all samples measuring ca. 60 nm. Spin-coated
491 glass coverslips were then placed into 12 well plates for ethylene oxide (EtO) sterilization, using 0.5
492 cc/L EtO at room temperature and 35% humidity for 12 hours with an Anprolene benchtop sterilizer
493 (Anderson Products, Inc., Haw River, NC), followed by a 48 hour purge.

494 Human Mesenchymal Stem Cells (*hMSCs*) and MC3T3 fibroblasts were expanded according to
495 the manufacturer's protocol and cultured in α -MEM supplemented with 10% FBS and 1% pen/strep
496 in incubators maintained at 37 °C with 5% CO₂. Media was changed every day for the duration of
497 culture.

498

499 **Cell Viability:** Cell viability was assessed using a Live/Dead® assay kit. *hMSCs* (passage 4) and
500 MC3T3 cells (passage 7) were seeded on spin coated coverslips ($n=5$) at 4000 cells/cm². After 24
501 hours the medium was removed and cells were stained using a Live/Dead® assay kit with 4 μ M
502 calcein AM (acetoxymethyl ester) and 2 μ M ethidium homodimer-1 in PBS, and incubated in the dark
503 at room temperature for 15 minutes before imaging using an Olympus IX81 inverted fluorescent
504 microscope equipped with a Hamamatsu Orca R² fluorescent camera and Olympus CellSens®
505 Dimension imaging software under TRITC (wavelength = 556/563 nm excitation/emission) and FITC
506 (wavelength = 490/525 nm excitation/emission) channels to obtain 10 images at 10 \times magnification of
507 each specimen. Live and dead cells were counted using NIH ImageJ. The number of live cells was
508 divided by the total number of cells on each specimen to obtain a percentage of cell viability.

509

510 **Cell Proliferation:** Cell proliferation of *hMSCs* seeded on spin-coated glass slides ($n=4$, 1000
511 cells/cm²) was evaluated by metabolic activity using a PrestoBlue® Assay following the supplier's
512 protocol. Metabolic activity was analyzed at 24 hours, 3 days and 7 days of culture. A standard curve
513 was prepared by seeding cell suspensions at known concentrations into 12 well plates at least 6
514 hours before the experiment to allow full attachment. Ten descending concentrations of cells
515 obtained by serial dilution and one blank were included in the standard curve. After removing the
516 medium, 1.5 mL of PrestoBlue® solution (10% in cell culture medium) was added to each well,
517 followed by incubation at 37 °C for 2-4 hours. Sample fluorescence was read when the fluorescence
518 from the standard curve gave a linear fit. 100 μ L of solution was taken from each well and placed in
519 triplicate into a 96-well plate. The fluorescence intensity (FI) was detected in a BioTek® Synergy™
520 MX Microplate Reader at wavelengths of 570 nm for excitation and 615 nm for emission. The

521 standard curve was fit with a linear relationship by plotting FI vs cell number, with a coefficient of
522 determination (R^2) above 0.99. The cell number was approximated using the obtained equation.

523

524 **Cell Seeding onto GRGDS Functionalized Polymer Thin Films:** Mouse calvarial stem cells
525 (MC3T3-E1, Passage 10) were cultured using MEM α (Gibco, Life Technologies) supplied with 10
526 vol % FBS, 100 units/mL penicillin, and 100 μ g/mL streptomycin at 37 °C and 5% CO₂. Cells were
527 subcultured every 3 days with a 0.25% (w/v) trypsin and 0.5% (w/v) EDTA solution. Polymer films
528 were sterilized by UV irradiation for 15 minutes, washed 3 times with PBS, and soaked with MEM α
529 for 2 h prior to cell seeding. Cells were seeded onto polymer thin films at 25,000 cells/cm² (n=4).

530

531 ***In Vivo* Characterization of Tissue Responses to Degradable Elastomers:** Elastomer samples
532 were prepared using vacuum film compression (Technical Machine Products Corporation) to press
533 0.5 mm thick films at 110 °C under 2,000 lbs of pressure for one hour. PLLA samples were pressed
534 at 200 °C for ten minutes under 10,000 lbs of pressure, ten minutes under 15,000 lbs of pressure,
535 and 10 minutes under 20,000 lbs of pressure. Elastomer samples all swelled after compression to be
536 approximately 1mm thick. PLLA films maintained 0.5mm thickness. After cooling, films were cut into
537 8 mm diameter discs and placed into 12 well plates for ethylene oxide (EtO) sterilization. Two weeks
538 prior to surgery, samples were sterilized with a dose of approximately 0.5 cc/L EtO at room
539 temperature and 35% humidity for 12 hours using an Anprolene benchtop sterilizer (Anderson
540 Products, Inc.) followed by a 48 hour purge.

541 Animals were handled and cared for in accordance with protocols that were approved by the
542 University of Akron Institutional Animal Care and Use Committee. Female Sprague-Dawley rats
543 (Harlan Laboratories) aged 60-80 days and weighing approximately 200-224 g were given one week
544 to acclimate to the facility before performing surgeries. General anesthesia was induced using a
545 cocktail of ketamine (29.6 mg/kg), xylazine (5.95 mg/kg) and acepromazine (0.53 mg/kg). Prior to
546 surgery rats were also given 0.02 mg/kg Buprenorphine, which was administered again every 12
547 hours as needed. The back was shaved and disinfected using several washes with povidone-iodine

548 solution and sterile alcohol wipes. Four 1 cm incisions were made, each 1 cm away from the spine
549 with at least 2 cm separating each incision to avoid sample crossover. A subcutaneous pocket was
550 created using curved hemostats to tunnel into the fascia space anterior to the incision. Each polymer
551 implant was placed into a pocket, and the incision was closed using Michel clips. An $n=6$ for each
552 polymer sample type was implanted per time point, with an $n=12$ for the PLLA control in order to
553 have one control sample per rat as direct comparison. The samples were randomized so that
554 analyses could be performed to check for interactions between samples implanted within the same
555 animal. Samples were implanted for 1 month, 2 months and 4 months.

556 Animals were euthanized using a fatal dose of sodium pentobarbital (0.5 cc per rat) at their
557 respective time points. A midline incision was made along the spine of the rat and between each
558 sample. Each sample was isolated, exposed, and photographed to observe macroscopic
559 inflammation before being removed and fixed in 4% paraformaldehyde overnight. After fixation
560 samples were rinsed for 15 minutes in distilled water three times, followed by three 15-minute rinses
561 in 70% ethanol. Samples were then processed into wax overnight using a tissue processor (Leica
562 ASP300 S, Leica Biosystems) before embedding in paraffin wax for sectioning.

563

564 **Histology staining and imaging:** Sections (8 to 14 μm thick) were stained for brightfield imaging
565 with hematoxylin and eosin (H&E), and modified Masson's trichrome. All images were taken with a
566 VS120-S6-W automated microscope equipped with both a CCD color camera and a fluorescence
567 Hamamatsu Orca-Flash4.0 fluorescence camera using DAPI (ex/em = 350/470 nm), FITC (ex/em =
568 490/525 nm) and TRITC (ex/em = 556/563 nm) filters. Brightfield images were analyzed for
569 inflammatory markers including granuloma thickness, and qualitatively assessed for general
570 inflammation compared to PLLA control samples. H&E slides were also analyzed under 400X light
571 microscopy for a number of inflammatory cells by a board-certified veterinary pathologist utilizing a
572 modified scoring system designed by the International Organization for Standardization (ISO 10993-
573 6 Annex E). Scoring was based on a scale from 0-4 (0 = none; 1 = Rare, 1-5 Minimal; 2 = 5-10,
574 Mild; 3 = Heavy Infiltrate, Moderate; 4 = Packed, Severe). The Macrophage analysis from

575 immunofluorescent images included qualitative assessment of cells located within the inflammatory
576 region surrounding the implants where CD68 was a positive indicator of a macrophage, CCR7
577 indicated primarily M1 expression, and CD206 indicated M2 expression. Samples that showed
578 tissue infiltration into the polymer space were stained with picosirius red to observe collagen
579 deposition and orientation. Images were taken using an Olympus IX70 microscope equipped with a
580 camera at 40× magnification under brightfield and polarized light conditions using Olympus
581 MicroSuite™ imaging software.

582

583 **Swelling Tests**

584 A film (0.5 mm thickness) of each elastomer was prepared from vacuum film compression using the
585 same method as stated above. Discs (4 mm) were cut from the film and placed in 1X PBS in the
586 incubator (37 °C, 5% CO₂ humidified atmosphere) for up to 32 days. The swelling behavior of the
587 elastomers were determined by tracking the wet and dry mass of the disc samples (n=3) at each
588 time point.

589

590 **STATISTICS**

591 Results are reported as mean ± standard deviation. One-way analysis of variance (ANOVA) with
592 Tukey's post-hoc was performed with a 95% confidence

593

594 **Author Contributions**

595 A.P.D., and M.L.B. conceived the project idea. C.A.B., A.P.D., and M.L.B. designed the materials
596 and synthetic routes while C.A.B., A.P.B. and Y-H.H. synthesized and characterized the materials.
597 C.B. and J.Y. performed thermal, mechanical analyses and *in vitro* degradation studies. M.B.W. and
598 M.L.B designed the *in vitro* and *in vivo* experiments. M.C.A., N.Z.D., Y-H. H. and M.B.W. prepared
599 samples and performed *in vitro* analyses. M.B.W., M.L.B. and N.Z.D. prepared samples, performed
600 *in vivo* analyses and performed the histology. A.P.D. and M.L.B. wrote the manuscript, all authors
601 edited and commented on the manuscript.

602

603 **Competing Interests**

604 A patent application was submitted in 2018 by MLB and APD covering some aspects of this work,
605 the other authors declare they have no competing interests.

606

607 **Data Availability Statement**

608 All raw spectroscopic and histology data is available from the corresponding author upon reasonable
609 request.

610

611 **References**

- 612 1 Chaudhuri, O. *et al.* Hydrogels with tunable stress relaxation regulate stem cell fate and
613 activity. *Nature Materials* **15**, 326-334 (2016).
- 614 2 Chen, Q., Liang, S. & Thouas, G. A. Elastic biomaterials for tissue engineering. *Progress*
615 *in Polymer Science* **38**, 584-671 (2013).
616
- 617 3 Nair, L. S. & Laurencin, C. T. Biodegradable polymers as biomaterials. *Progress in*
618 *Polymer Science* **32**, 762-798 (2007).
- 619 4 Mainil-Varlet, P., Gogolewski, S. & Neiuwenhuis, P. Long-term soft tissue reaction to
620 various polylactides and their in vivo degradation. *J. Mater. Sci. Mater. Med.* **7**, 713-721
621 (1996).
- 622 5 Worch, J. C. *et al.* Elastomeric polyamide biomaterials with stereochemically tuneable
623 mechanical properties and shape memory. *Nat Commun* **11**, 3250 (2020).
- 624 6 Worch, J. C. *et al.* Stereochemical enhancement of polymer properties. *Nature Reviews*
625 *Chemistry* **3**, 514-535 (2019).
- 626 7 Ribeiro, S. *et al.* Electrospun styrene–butadiene–styrene elastomer copolymers for
627 tissue engineering applications: Effect of butadiene/styrene ratio, block structure,
628 hydrogenation and carbon nanotube loading on physical properties and cytotoxicity.
629 *Composites Part B: Engineering* **67**, 30-38 (2014).

- 630 8 Cohn, D., Lando, G., Sosnik, A., Garty, S. & Levi, A. PEO–PPO–PEO-based poly(ether
631 ester urethane)s as degradable reverse thermo-responsive multiblock copolymers.
632 *Biomaterials* **27**, 1718-1727 (2006).
- 633 9 Dempsey, D. K. *et al.* Characterization of a resorbable poly(ester urethane) with
634 biodegradable hard segments. *J. Biomat. Sci. Polym. Ed.* **25**, 535-554 (2014).
- 635 10 Guan, J., Sacks, M. S., Beckman, E. J. & Wagner, W. R. Biodegradable poly(ether ester
636 urethane)urea elastomers based on poly(ether ester) triblock copolymers and
637 putrescine: synthesis, characterization and cytocompatibility. *Biomaterials* **25**, 85-96
638 (2004).
- 639 11 Guan, J. & Wagner, W. R. Synthesis, Characterization and Cytocompatibility of
640 Polyurethaneurea Elastomers with Designed Elastase Sensitivity. *Biomacromolecules* **6**,
641 2833-2842 (2005).
- 642 12 Hong, Y. *et al.* Tailoring the degradation kinetics of poly(ester-carbonate urethane)urea
643 thermoplastic elastomers for tissue engineering scaffolds. *Biomaterials* **31**, 4249-4258
644 (2010).
- 645 13 Liu, Q., Jiang, L., Shi, R. & Zhang, L. Synthesis, preparation, in vitro degradation, and
646 application of novel degradable bioelastomers—A review. *Progress in Polymer Science*
647 **37**, 715-765 (2012).
- 648 14 Montgomery, M. *et al.* Flexible shape-memory scaffold for minimally invasive delivery of
649 functional tissues. *Nature Materials* **16**, 1038-1046 (2017).
- 650 15 Stankus, J. J., Guan, J. & Wagner, W. R. Fabrication of biodegradable elastomeric
651 scaffolds with sub-micron morphologies. *J. Biomat. Mater. Res. A.* **70**, 603-614 (2004).
- 652 16 Tatai, L. *et al.* Thermoplastic biodegradable polyurethanes: The effect of chain extender
653 structure on properties and in-vitro degradation. *Biomaterials* **28**, 5407-5417 (2007).
- 654 17 Wang, Y., Ameer, G. A., Sheppard, B. J. & Langer, R. A tough biodegradable elastomer.
655 *Nature Biotechnologies* **20**, 602-606 (2002).
- 656 18 Widjaja, L. K. *et al.* Triblock copolymers of ϵ -caprolactone, L-lactide, and trimethylene
657 carbonate: biodegradability and elastomeric behavior. *J. Biomed. Mater. Res. A.* **99**, 38-
658 46 (2011).

- 659 19 Wu, W., Allen, R. A. & Wang, Y. Fast degrading elastomer enables rapid remodeling of a
660 cell-free synthetic graft into a neo-artery. *Nature Medicine* **18**, 1148-1153 (2012).
- 661 20 Yildirimer, L. *et al.* Controllable degradation kinetics of POSS nanoparticle-integrated
662 poly(ϵ -caprolactone urea)urethane elastomers for tissue engineering applications.
663 *Scientific Reports* **5**, 15040 (2015).
- 664 21 Zhang, B. *et al.* Biodegradable scaffold with built-in vasculature for organ-on-a-chip
665 engineering and direct surgical anastomosis. *Nature Materials* **15**, 669-678 (2016).
- 666 22 Zhang, S. *et al.* pH-responsive supramolecular polymer gel as an enteric elastomer for
667 use in gastric devices. *Nature Materials* **14**, 1065-1071 (2015).
- 668 23 Zhang, Z., Grijpima, D. W. & Feijen, J. Triblock Copolymers Based on 1,3-Trimethylene
669 Carbonate and Lactide as Biodegradable Thermoplastic Elastomers. *Macromol. Chem.*
670 *Phys.* **205**, 867-875 (2004).
- 671 24 Santerre, J. P., Woodhouse, K., Laroche, G. & Labow, R. S. Understanding the
672 biodegradation of polyurethanes: From classical implants to tissue engineering
673 materials. *Biomaterials* **26**, 7457-7470 (2005).
- 674 25 Mathur, A. B. *et al.* In vivo biocompatibility and biostability of modified polyurethanes. *J.*
675 *Biomed. Mater. Res.* **36**, 246-257 (1997).
- 676 26 Li, X., Hong, A. T., Naskar, N. & Chung, H. J. Criteria for Quick and Consistent
677 Synthesis of Poly(glycerol sebacate) for Tailored Mechanical Properties.
678 *Biomacromolecules* **16**, 1525-1533 (2015).
- 679 27 Liu, Q., Tan, T., Weng, J. & Zhang, L. Study on the control of the compositions and
680 properties of a biodegradable polyester elastomer. *Biomed. Mater.* **4**, 025015 (2009).
- 681 28 Wang, Y., Kim, Y. M. & Langer, R. In vivo degradation characteristics of poly(glycerol
682 sebacate). *J. Biomed. Mater. Res. A.* **66A**, 192-197 (2003).
- 683 29 Bell, C. A. *et al.* Independent Control of Elastomer Properties through Stereocontrolled
684 Synthesis. *Angew Chem Int Ed Engl* **55**, 13076-13080, doi:10.1002/anie.201606750
685 (2016).
- 686 30 Benit, P. *et al.* Unsuspected task for an old team: Succinate, fumarate and other Krebs
687 cycle acids in metabolic remodeling. *Biochimica et Biophysica Acta - Bioenergetics*
688 **1837**, 1330-1337 (2014).

- 689 31 Tang, W. & Becker, M. L. "Click" reactions: a versatile toolbox for the synthesis of
690 peptide conjugates. *Chemical Society Reviews* **43**, 7013-7039, doi:DOI:
691 10.1039/c4cs00139g (2014).
- 692 32 Boren, B. C. *et al.* Ruthenium-Catalyzed Azide-Alkyne Cycloaddition: Scope and
693 Mechanism. *J. Amer. Chem. Soc.* **130**, 8923-8930 (2008).
- 694 33 Dreger, N. Z. *et al.* Amino acid-based Poly(ester urea) copolymer films for hernia-repair
695 applications. *Biomaterials* **182**, 44-57, doi:10.1016/j.biomaterials.2018.08.003 (2018).
- 696 34 Dreger, N. Z. *et al.* Preclinical in Vitro and in Vivo Assessment of Linear and Branched L-
697 Valine-Based Poly(ester urea)s for Soft Tissue Applications. *ACS Biomaterials Science*
698 *& Engineering* **4**, 1346-1356, doi:10.1021/acsbiomaterials.7b00920 (2018).
- 699 35 Rhee, H. J., Hillebrands, W. & Daems, W. T. Are Langhans giant cells precursors of
700 foreign-body giant cells? *Arch. Dermatol. Res.* **263**, 13-21 (1978).
- 701 36 Sheikh, Z., Brooks, P. J., Barzilay, O., Fine, N. & Glogauer, M. Macrophages, foreign
702 body giant cells and their response to implantable biomaterials. *Materials* **8**, 5671-5701
703 (2015).
- 704 37 Witherel, C. E., Abeyayehu, D., Barker, T. H. & Spiller, K. L. Macrophage and Fibroblast
705 Interactions in Biomaterial-Mediated Fibrosis. *Adv. Healthc. Mater.* **8**, e1801451 (2019).
- 706 38 Maluf-Meiken, L. C. V., Silva, D. R. & Duek, E. A. R. Morphometrical analysis of
707 multinucleated giant cells in subdermal implants of poly-lactic acid in rats. *J. Mater. Sci.*
708 *Mater. Med.* **17**, 481-485 (2006).
- 709 39 Vogel, B., Siebert, H., Hofmann, U. & Frantz, S. Determination of collagen content within
710 picosirius red stained paraffin-embedded tissue sections using fluorescence
711 microscopy. *MethodsX* **2** (2015).
- 712 40 Pomerantseva, I. *et al.* Degradation behavior of poly(glycerol sebacate). *J. Biomat.*
713 *Mater. Res. A.* **91A**, 1038-1047 (2009).
- 714 41 O'Brian, F. J. Biomaterials & scaffolds for tissue engineering. *Mater. Today* **14**, 88-95
715 (2011).
716
717

718 **Figure 1. Stereocontrolled synthesis and characterization of the resorbable elastomers.** (A) A
719 one-pot thiol-yne step-growth polymerization of propane-1,3-diyl dipropiolate (C_{3A}, **1**) with bis(3-
720 mercaptopropyl) succinate (**2**) and with 1,6-hexane dithiol (C_{6S}) forms a copolymer that shows
721 tunable degradation rates depending on the % of amount of repeat unit x (**1** + **2**) that is incorporated.
722 (B) The stereochemistry is easily determined by the vinyl proton doublets at $\delta = 5.7$ and 7.7 ppm
723 (*trans*, 15 Hz) and $\delta = 5.8$ and 7.1 ppm (*cis*, 9 Hz), respectively. The extent of succinate
724 incorporation will determine both the rate and extent of degradation.
725

726 **Figure 2. Compositional-dependent mechanical properties of the resorbable polymers** (A)
727 Mass loss as a function bis(3-mercaptopropyl) succinate (**2**) stoichiometry over time in a series of
728 high *cis* (78-79%) elastomers show compositionally dependent linear surface erosion behavior. (B)
729 Increasing the amount of bis(3-mercaptopropyl) succinate (**2**) which is a longer, bulkier comonomer
730 reduced the UTS of the resulting elastomers. Mechanical properties and degradation rates are highly
731 tunable depending on the amount of *cis*-alkene bonds in the backbone and stoichiometric control of
732 succinate content. Succinate groups in the chemical structure provide flexibility and hydrophilicity to
733 the polymer chains and facilitate the degradation process. The increase in chain mobility and
734 hydrophilicity results in an increase of the number of degradable ester groups and hence the
735 degradation rates (C) and a decrease of Young's modulus (D). Increasing the *cis*-alkene content
736 resulted in slower degradation rates and higher Young's moduli values, decreased ultimate strain.
737 Error bars represent one standard deviation of the mean (n=3).
738

739 **Figure 3. Surface Erosion and Swelling** (A) Discs (4 mm, 0.5mm thick) were cut from vacuum film
740 compression samples and placed in 1X PBS in the incubator (37 °C, 5% CO₂ humidified
741 atmosphere) for up to 32 days. The data was plotted in three different ways: dry mass change
742 compared to the original mass (degradation), wet mass change compared to the original
743 mas (traditional swelling if no degradation) and wet mass/dry mass at each time point (swelling if
744 degradation). The swelling behavior of the polymers were determined by tracking the wet and dry
745 mass of the disc samples at each time point. Error bars represent one standard deviation of the
746 mean (n=4) (B) Analysis of SEM micrographs of the respective test coupons exposed to accelerated
747 degradation conditions indicates uniform degradation and pitting indicative of surface erosion
748 processes. Scale bars = 10 μ m.
749

750 **Figure 4. Cell Viability and Post polymerization Functionalization.** **A)** Live/Dead® staining of
751 cells incubated on each substrate for 24 hours. Calcein-AM was used to stain live cells (green) and
752 ethidium homodimer-1 was used for dead cells (red). Scale Bars are 200 μ m. **B)** Representative
753 fluorescence pictures of hMSCs cultured on degradable polymer substrates for 72 h. Scale bars are
754 200 μ m. **C)** Quantitative cell viability data showed >95% viability after 24 hours in both hMSCs and
755 MC3T3 fibroblasts. Error bars represent one standard deviation of the mean (n=5). **D)** Cell
756 metabolic activity showed an increase in approximate cell number on degradable polymer substrates
757 over 7 days. Error bars represent one standard deviation of the mean (n=5). **E)** To demonstrate the
758 ability to derivatize the polymers post polymerization, a Megastokes®-673-azide dye surrogate
759 specifically binds to the internal alkyne functionalized polymer **F)**. Scale bar is 500 μ m. Cell
760 spreading on (poly(bis(4-(propioloyloxy)but-2-yn-1-yl)-3,3'-(hexane-1,6-diylbis(sulfanediy)))) films
761 without (**G**) and with (**H**) RGD functionalization. Increased cell adhesion, spreading and integrin-
762 associated actin fiber formation was evident in the RGD derivatized films, indicating that RGD
763 conjugation was successful. Scale bars are 100 μ m.
764

765 **Figure 5.** Subcutaneous *in vivo* degradation of Poly(L-lactic acid) (PLLA), 80% *cis* / 50% succinate
766 and 80% *cis* / 100% succinate over a 4-month timeframe. Surgical procedures with subcutaneous

767 implantation involved a small incision, polymer disc insertion, and incision closure with Michel-clips.
768 Four samples were implanted per animal (A). (B) Following extraction, the implants can be
769 visualized in the host tissue using Hematoxylin and Eosin (H&E) and Masson's Trichrome staining.
770 As seen, there are almost no macroscopic indications of an inflammatory response. Whole-mount
771 cross-section images showing thick fibrous encapsulation surrounding PLLA after 4 months of
772 incubation *in vivo* are observed. Similar behavior to PLLA is observed for 80% cis / 50% succinate at
773 1- and 4-months implantation. Alternatively, the early stages of cellular infiltration are noticed in 80%
774 cis / 100% succinate after only 1 month (I). After 2- (Supplementary Figure 23) and 4- months,
775 noticeable shrinking/resorption of the polymer was seen with continued cellular infiltration.
776 Degradation after 4 months is nearly complete with cells, deposited collagen and tissue fully
777 encompassing the polymer area. Blood vessel sprouts and multinucleated giant cells are noticeable
778 throughout the polymer space that has been resorbed. Trichrome images show collagen deposition
779 and immunohistochemistry staining macrophages for pro-inflammatory (**M1**), non-activated (**M0**) and
780 anti-inflammatory (**M2**) macrophages show degradation induced inflammation and remodeling. Inset
781 scale bar = 200 μ m. Shown micrographs are representative of histology specimens (n=4) from each
782 of six independent implants (n=6) for each material.
783

784 **Figure 6.** Picosirius Red staining of 80cis:100suc elastomers after 1 month and 4 months of
785 subcutaneous incubation. Collagen deposition and maturation occurred throughout the polymer
786 space with different orientations representing both mature and developing collagen through the
787 center of the polymer area. Scale bars are 100 μ m. Shown micrographs are representative of
788 histology specimens (n=4) from each of six independent implants (n=6) for each material.
789

790

791

792

793

794

795

796

797

798

799

800 **Table 1** – Polymerization conditions and characterization of all thiol-yne step growth polymers

Entry	% feed of 2	% incorporation	Monomer ratio ^a	Solvent	Base	Time (h)	% cis ^b	M _n (kDa)	M _w (kDa)	801 D _M
1	0	0	0.9965	CHCl ₃	DBU	1	80	26.4	147.5	802
2	9.0	9.0	0.9920	CHCl ₃	DBU	1	80	29.7	111.2	3.74
3	19.9	18.7	0.9922	CHCl ₃	DBU	1	79	35.2	110.8	803 3.15
4	50.5	49.4	0.9895	CHCl ₃	DBU	1	79	52.5	123.7	804 3.16
5	100	100	0.9870	CHCl ₃	DBU	1	79	35.9	112.2	3.12
6	19.8	19.0	0.9920	DMF	Et ₃ N	16	72	43.0	127.3	805 2.96
7	0	0	0.9920	CHCl ₃ /DMF (7:3)	Et ₃ N	16	62	37.0	110.8	3.00
8	11.2	8.7	0.9959	CHCl ₃ /DMF (7:3)	Et ₃ N	16	62	34.2	117.1	806 3.42
9	19.6	18.3	0.9920	CHCl ₃ /DMF (7:3)	Et ₃ N	16	61	35.3	107.8	807 3.05
10 ^c	0	0	0.9950	CHCl ₃	DBU	1	80	24.7	35.4	1.46 808

809 ^a An excess of the dialkyne monomer was used to reduce any disulfide coupling and UV crosslinking side reactions

810 ^b Determined by comparison of ¹H NMR integration of *cis* peaks at 7.10 ppm and *trans* peaks at 7.70 ppm

811 ^c Synthesis conditions for poly(bis(4-(propioloyloxy)but-2-yn-1-yl) 3,3'-(hexane-1,6-diylbis(sulfanediyl)))

812

813

814

815

816

817

818

819

820 **Table 2.** SEC, thermal and mechanical characterization of the degradable elastomers synthesized by step-growth polymerization
 821 incorporating **2**.

% <i>cis</i> ^a	% incorporation of 2	M_n (kDa)	M_w (kDa)	D_M	T_g (°C)	T_m (°C)	E (MPa)	ϵ_{break} (%)	UTS (MPa)
80	9.0	29.7	111.2	3.74	1.7	71.4	33.1 ± 3.3	1457 ± 312	34.9 ± 8.7
79	18.7	35.2	110.8	3.15	-0.7	50.0	21.1 ± 0.7	1750 ± 163	30.1 ± 5.5
79	49.4	52.5	123.7	2.36	-0.6	-	2.2 ± 0.4	2161 ± 158	18.9 ± 3.1
78	58.4	57.8	155.6	2.69	-2.7	-	1.8 ± 0.4	3154 ± 330	14.6 ± 1.3
78	79.1	29.2	132.7	4.55	-2.3	-	1.9 ± 0.2	2805 ± 149	10.9 ± 0.3
79	100	35.9	112.2	3.12	-5.1	-	1.6 ± 0.2	2245 ± 1135	0.8 ± 0.4
62	8.7	34.2	117.1	3.42	-8.1	-	2.1 ± 0.3	1088 ± 320	8.9 ± 3.5
80	9.0	29.7	111.2	3.74	1.7	71.4	33.1 ± 3.3	1457 ± 312	34.9 ± 8.7
79	49.4	52.5	123.7	2.36	-0.6	-	2.2 ± 0.4	2161 ± 158	18.9 ± 3.1
72	19.0	43.0	127.3	2.96	-0.2	49.4	3.2 ± 0.7	2158 ± 247	17.6 ± 3.9

822

823 ^a Determined by comparison of ¹H NMR spectroscopy integration of *cis* peaks at 5.8 ppm and 7.1 ppm and *trans* peaks at 5.7 ppm and 7.7
 824 ppm.

825

826

827

828

829

830

831



832





833 **Table 3.** Modified 10993-6 Inflammatory histological Response Analysis

Cell Type Response	PLLA			62/10			80/10			80/50			80/100		
	1 Month	2 Month	4 Month	1 Month	2 Month	4 Month	1 Month	2 Month	4 Month	1 Month	2 Month	4 Month	1 Month	2 Month	4 Month
Neutrophils	0.3±0.5	0.6±0.9	0.2±0.4	0.1±0.3	0.6±0.7	0.2±0.4	0.1±0.2	0.7±0.9	0.1±0.2	0.4±0.5	0.9±1.0	0.3±0.5	0.4±0.5	1.1±0.6	0.1±0.2
Lymphocytes	2.5±0.6	2.0±0.7	2.2±0.7	2.8±0.5	2.2±0.7	2.2±0.8	2.7±0.5	2.4±0.8	2.0±0.6	3.7±0.4	1.8±0.8	1.9±0.8	3.7±0.4	2.8±0.7	3.2±0.7
Plasma Cells	0.1±0.2	0.1±0.3	0±0	0.1±0.2	0.1±0.2	0±0	0±0	0±0	0.1±0.2	0.6±0.6	0.3±0.4	0±0	0.6±0.6	0±0	1.4±0.6
Single Macrophages	1.9±1.2	0±0	1.5±1.4	1.6±1.3	1.0±0.9	1.1±1.2	1.6±1.1	1.2±0.9	0.5±0.8	2.9±0.2	1.7±1.1	0.5±0.9	2.9±0.2	1.4±1.0	3.8±0.4
Multinucleated Giant Cells	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0.9±0.5	0.1±0.2	0±0	0.9±0.5	0.1±0.2	2.5±0.9
Necrosis	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0	0±0
	4.8±1.6	4.0±1.6	4.0±2.0	4.6±1.7	3.8±1.4	3.5±1.6	4.3±1.2	4.2±2.0	2.6±1.3	4.9±1.8	4.7±1.7	2.7±1.2	8.6±1.5	9.1±1.2	10.9±1.9


834

835











Dry




Wet








Swollen

















60c10s 70c20s 80c10s 80c20s 80c50s 80c100s





	H&E		Trichrome	Macrophage (M0, M1, M2)
	1 month	4 month	4 month	4 month
PLLA				
80%/50% (cis/succ.)				
80%/100% (cis/succ.)				

SB: 200 μ m

1 month

4 month

